Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
EyePoint Pharmaceuticals ( (EYPT) ) has shared an announcement.
On December 8, 2025, EyePoint, Inc. officially changed its name from EyePoint Pharmaceuticals, Inc. This change, which also involved amendments to the company’s by-laws, does not impact the trading of its common stock on the Nasdaq Global Market under the ticker symbol ‘EYPT’, nor does it affect the rights of the company’s security holders.
The most recent analyst rating on (EYPT) stock is a Hold with a $18.50 price target. To see the full list of analyst forecasts on EyePoint Pharmaceuticals stock, see the EYPT Stock Forecast page.
Spark’s Take on EYPT Stock
According to Spark, TipRanks’ AI Analyst, EYPT is a Neutral.
EyePoint Pharmaceuticals’ overall stock score reflects significant financial challenges, with declining revenues and persistent losses impacting profitability. However, strong technical indicators and positive corporate events, including successful trial updates and financing, provide a counterbalance. The company’s strategic focus on innovative treatments and clinical advancements positions it for potential future growth, despite current valuation concerns.
To see Spark’s full report on EYPT stock, click here.
More about EyePoint Pharmaceuticals
EyePoint, Inc. operates within the pharmaceutical industry, focusing on the development and commercialization of innovative ophthalmic products. The company is known for its efforts in addressing unmet medical needs in eye care.
Average Trading Volume: 1,277,747
Technical Sentiment Signal: Buy
Current Market Cap: $1.47B
Find detailed analytics on EYPT stock on TipRanks’ Stock Analysis page.